Wilson Sonsini Goodrich & Rosati has advised Oak Hill Bio on IP matters. Cooley has advised Research Alliance Corporation III (RACC). OHB Pediatrics Ltd., operating as...
Oak Hill Bio and RACC Announce $175 Million Business Combination to Form Nasdaq-Listed Rare Disease Company
Sagard Healthcare Partners’ $250 Million Non-Dilutive Financings to Nuvation Bio
Cooley represented Nuvation Bio in the transaction, and Sidley Austin represented Sagard Healthcare Partners. Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the...
Kura Oncology’s Collaboration with Kyowa Kirin
Wilson Sonsini Goodrich & Rosati and Cooley advised Kura Oncology. Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...
PSI Group’s Business Combination with AIB Acquisition Corporation
Cooley LLP is serving as U.S. legal advisor, and Ogier is serving as Cayman Islands legal advisor to PSI Group Holdings Ltd in the transaction, while...
SystImmune’s Licensing and Collaboration Agreement with Bristol Myers Squibb
Cooley advised SystImmune on the transaction. SystImmune announced its exclusive license and collaboration agreement with Bristol Myers Squibb (NYSE: BMY) for SystImmune’s BL-B01D1. Under the terms of...
Vietnam Sunergy Cell Company’s Business Combination with Blue World Acquisition
Cooley acted as U.S. legal advisor to Vietnam Sunergy Cell Company, and Robinson & Cole acted as U.S. legal advisor to Blue World. Vietnam Sunergy Cell...
Turnstone Biologics Corp.’s $80 Million Initial Public Offering
Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
Roche’s Acquisition of Zion Pharma’s Lead Program Title
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
SoundHound AI’s $125 Million New Loan Facility From Atlas Credit Partners
Cooley advised SoundHound AI on the deal. SoundHound AI, a leader in voice artificial intelligence, announced the closing of a new $125 million loan facility from...
SCYNEXIS’ License Agreement With GSK for Brexafemme
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
Redx Pharma’s Merger with Jounce Therapeutics
Cooley advised Redx Pharma on the deal while Ropes & Gray has advised Jounce Therapeutics, Inc. Redx Pharma, a UK clinical-stage biotechnology company, announced its all share...
Structure Therapeutics’ $185.3 Million IPO
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...